Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bonneterre

Showing results (111-120 of 194) with videos related to

Pageof 20
Sort By:
Breast Cancer Research and Treatment|January 1, 1984
Characterization of prolactin receptors in human breast cancerJ P Peyrat, J Djiane, P A Kelly, et al.
Pathologie-Biologie|November 1, 1984
[Receptors for steroid hormones apart from breast cancer. Practical value]P Vennin, J P Peyrat, J Bonneterre, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future researchR D Rubens, E Bajetta, J Bonneterre, et al.
LARC Medical|October 1, 1984
[Hormonal receptors and breast cancer. Results on 589 patients]J Bonneterre, J P Peyrat, B Vandewalle, et al.
British Journal of Cancer|August 1, 1995
Analysis of p16 gene deletion and point mutation in breast carcinomaB Quesnel, P Fenaux, N Philippe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancerM Degardin, J Bonneterre, B Hecquet, et al.
British Journal of Cancer|November 20, 2002
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failureJ Bonneterre, H Roché, A Monnier, et al.
Cancer Chemotherapy and Pharmacology|May 28, 2003
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancerS Urien, P Fumoleau, M Campone, et al.
Anticancer Research|January 1, 1989
Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancerP Vennin, J P Peyrat, J Bonneterre, et al.
Bulletin Du Cancer|January 1, 1995
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy]M Hebbar, B Hecquet, L Vanlemmens, et al.
Pageof 20

Showing results (111-120 of 194) with videos related to

Sort By:
Pageof 20
Breast Cancer Research and Treatment|January 1, 1984
Characterization of prolactin receptors in human breast cancerJ P Peyrat, J Djiane, P A Kelly, et al.
Pathologie-Biologie|November 1, 1984
[Receptors for steroid hormones apart from breast cancer. Practical value]P Vennin, J P Peyrat, J Bonneterre, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future researchR D Rubens, E Bajetta, J Bonneterre, et al.
LARC Medical|October 1, 1984
[Hormonal receptors and breast cancer. Results on 589 patients]J Bonneterre, J P Peyrat, B Vandewalle, et al.
British Journal of Cancer|August 1, 1995
Analysis of p16 gene deletion and point mutation in breast carcinomaB Quesnel, P Fenaux, N Philippe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1994
Vinorelbine (navelbine) as a salvage treatment for advanced breast cancerM Degardin, J Bonneterre, B Hecquet, et al.
British Journal of Cancer|November 20, 2002
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failureJ Bonneterre, H Roché, A Monnier, et al.
Cancer Chemotherapy and Pharmacology|May 28, 2003
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancerS Urien, P Fumoleau, M Campone, et al.
Anticancer Research|January 1, 1989
Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancerP Vennin, J P Peyrat, J Bonneterre, et al.
Bulletin Du Cancer|January 1, 1995
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy]M Hebbar, B Hecquet, L Vanlemmens, et al.
Pageof 20